Side effects

5 October 2009. Related: Conference reports, Side effects.

Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r

3 June 2009. Related: Conference reports, Side effects.

Intensive smoking cessation programme reports limited success at 6 months

3 June 2009. Related: Conference reports, Side effects.

HDL particle concentration predicts cardiovascular disease in SMART

3 June 2009. Related: Conference reports, Side effects.

CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya

3 June 2009. Related: Conference reports, Side effects.

Genetic markers linked to early discontinuation of three antiretrovirals

3 June 2009. Related: Conference reports, Side effects.

High rate of rash in HIV negative volunteers combining raltegravir and darunavir

26 December 2008. Related: Conference reports, Side effects.

Bone loss in SMART study

26 December 2008. Related: Conference reports, Side effects.

Parathyroid hormone and vitamin D levels in patients using tenofovir

26 December 2008. Related: Conference reports, Side effects.

Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy

26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Statin use in HIV-positive patients

26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease

30 October 2008. Related: Conference reports, Antiretrovirals, Side effects.

EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)

30 October 2008. Related: Antiretrovirals, Side effects.

Ritonavir label updated in the US relating to cardiac arrhythmia reported in high-dose studies

30 October 2008. Related: Antiretrovirals, Side effects.

Bone problems raised in several UK studies

30 August 2008. Related: Conference reports, Side effects.

New-fill used to treat lipoatropy in feet

12 June 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Case report of efavirenz-associated nephrolithiasis

1 December 2007. Related: Side effects.

Yellow card reporting scheme for doctors and patients in the UK

1 December 2007. Related: Side effects.

30 cases of atazanavir-related kidney stones reported

3 July 2007. Related: Side effects.

Tenofovir and indinavir associated with increased risk of chronic renal failure in EuroSIDA study

3 July 2007. Related: Side effects.

Growth hormone release factor (TH9507) reduces central fat adiposity

4 April 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Further insight into risk and management of cardiovascular disease (CVD) from D:A:D cohort: no additional benefit of metabolic syndrome diagnosis; new HIV-specific CVD risk equations; increasing uptake of lipid lowering drugs but low smoking cessation

4 April 2007. Related: Conference reports, Side effects.

d4T associated with significantly increased risk of type-2 diabetes mellitus

6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia

6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

The role of the metabolic syndrome in HIV

15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome

9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat

9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin

9 September 2006. Related: Conference reports, Side effects, Cancer and HIV.

Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions

12 May 2006. Related: Conference reports, Side effects.

Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa

12 May 2006. Related: Conference reports, Side effects.

D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy

25 March 2006. Related: Conference reports, Side effects.

Interventions for the management of lipodystrophy and metabolic complications

25 March 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand

11 February 2006. Related: Conference reports, Side effects.

Factors associated with sexual dysfunction in HIV patients

11 February 2006. Related: Conference reports, Side effects.

African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects

10 February 2006. Related: Conference reports, Side effects.

Predictors of insulin resistance in first year of therapy

10 February 2006. Related: Conference reports, Side effects.

Monitoring side effects in resource limited countries

13 December 2005. Related: Conference reports, Side effects.

Uridine supplement reverses thymidine-induced lipoatrophy

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Niacin has beneficial effect on lipids but no reduction in abdominal fat

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Gluteal implants used to replace lost buttock fat

13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy

13 October 2005. Related: Side effects.

EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients

13 September 2005. Related: Side effects.

EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection

13 September 2005. Related: Side effects, Hepatitis coinfection.

Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin

15 June 2005. Related: Conference reports, PK and drug interactions, Side effects.

Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age

18 April 2005. Related: Conference reports, Side effects.

Omega-3 supplement effective to reduce triglycerides

18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir

18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy

18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects

29 March 2005. Related: Conference reports, Side effects.

Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Potential for uridine to treat mitochondrial toxicity: still only in vitro data

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

rHGH reduces central fat accumulation in adolescent lipodystrophy

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Endothelial dysfunction similar in ARV-experienced and -naive patients

31 January 2005. Related: Conference reports, Side effects.

Pravastatin improves lipid profiles but not endothelial function

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Improvement of lipids following switch to tenofovir

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Restorative treatments for HIV-associated lipoatrophy

31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.

Side effects update: hypersensitivity, heart, bones

29 January 2005. Related: Conference reports, Side effects.

Vancouver researchers urge caution with combinations of lipid drugs

6 November 2004. Related: Side effects, Lipodystrophy and metabolic complications.

Post navigation